Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Ipsen scuttles liver disease candidates from $952M Albireo acquisition

Ipsen scuttles liver disease candidates from $952M Albireo acquisition

  • May 6, 2026

Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.

Leave A Comment

Fields (*) Mark are Required